-
A new transdermal formulation of oxybutynin has been approved for the treatment of overactive bladder. Oxybutynin gel is marketed by Watson Pharmaceuticals as Gelniqueä.
-
A severe ankle sprain (ANK-S) might seem like a minor injury, but clinicians may be underestimating the burden of consequence.
-
Regardless of proportions of fat, protein, and carbohydrate, all diets with lowered caloric intake modestly reduced weight.
-
An elevated resting heart rate is a risk factor for heart disease.
-
The joint cardiovascular practice guidelines of the American College of Cardiology (ACC) and the American Heart Association (AHA) are largely based on expert opinion, case studies, or "standard of care," rather than on scientific evidence.
-
Ranolazine has gained expanded approval from the FDA for the treatment of chronic angina.
-
The ECG shown above was obtained from a 60-year-old woman who presented with an acute stroke. Is her ECG consistent with this diagnosis, and/or suggestive of something more?
-
The first new urate-lowering drug has been approved in more than 40 years.
-
A prospective study of men and women showed that duration of sleep is correlated with coronary artery calcification with 1 hour more of sleep daily reducing the odds of calcification over 5 years by 33%.
-
Utilizing genotyping for warfarin therapy in patients with non-valvular atrial fibrillation may not be cost-effective.
